Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: A-007

Latest Information Update: 20 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Barbara Ann Karmanos Cancer Institute; Dekk-Tec
  • Developer Kirax Corporation
  • Class Antineoplastics; Hydrazones; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anal intraepithelial neoplasia; Breast cancer; Cervical cancer; Cervical intraepithelial neoplasia; Kaposi's sarcoma; Lymphoma; Malignant melanoma

Most Recent Events

  • 03 Jul 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events section
  • 18 Jan 2007 Tigris Pharmaceuticals completes enrolment in the phase I/II trial for Anal intraepithelial neoplasia in USA
  • 18 Jan 2007 Tigris Pharmaceuticals completes enrolment in two registrational clinical trials for Cervical intraepithelial neoplasia in Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top